Alnylam Pharmaceuticals (ALNY) Other Non-Current Assets (2011 - 2026)
Alnylam Pharmaceuticals' (ALNY) quarterly Other Non-Current Assets came in at $65.1 million in Q2 2026, up 13.92% YoY from $57.2 million in Q2 2025, and up 2.48% on a QoQ basis from $63.6 million in Q1 2026.
Alnylam Pharmaceuticals (ALNY) Other Non-Current Assets (2011 - 2026) Analysis & Trends
Alnylam Pharmaceuticals (ALNY) has 14 years of Other Non-Current Assets data on file, last reported at $65.1 million in Q2 2026.
- Quarterly Other Non-Current Assets rose 13.92% year-over-year to $65.1 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $65.1 million (up 13.92% YoY) and the FY2025 annual result came in at $59.5 million, down 8.96% from the prior year.
- Other Non-Current Assets climbed to $65.1 million in Q2 2026, from $63.6 million in the prior quarter.
- In the past five years, Other Non-Current Assets ranged from a high of $92.7 million in Q2 2023 to a low of $55.8 million in Q3 2025.
- A 5-year average of $68.1 million and a median of $65.7 million in 2022 frame the typical range for Other Non-Current Assets.
- Annual changes were most pronounced in 2022 — Other Non-Current Assets surged 123.4% — and 2025, when it fell 28.06%.
- Tracing ALNY's Other Non-Current Assets over 5 years: stood at $66.1 million in 2022, then decreased by 6.34% to $61.9 million in 2023, then rose by 5.51% to $65.3 million in 2024, then fell by 8.96% to $59.5 million in 2025, then climbed by 9.54% to $65.1 million in 2026.
- The last three Other Non-Current Assets figures came in at $65.1 million (Q2 2026), $63.6 million (Q1 2026), and $59.5 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 124.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 42.45 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 109.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 18,237.65 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 62.96 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 65.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 104.44 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 29.59 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 65.13 Mn |
| Mar 31, 2026 | 63.55 Mn |
| Dec 31, 2025 | 59.46 Mn |
| Sep 30, 2025 | 55.84 Mn |
| Jun 30, 2025 | 57.17 Mn |
| Mar 31, 2025 | 73.82 Mn |
| Dec 31, 2024 | 65.31 Mn |
| Sep 30, 2024 | 77.62 Mn |
| Jun 30, 2024 | 71.93 Mn |
| Mar 31, 2024 | 67.46 Mn |
| Dec 31, 2023 | 61.90 Mn |
| Sep 30, 2023 | 75.16 Mn |
| Jun 30, 2023 | 92.69 Mn |
| Mar 31, 2023 | 63.45 Mn |
| Dec 31, 2022 | 66.09 Mn |
| Sep 30, 2022 | 61.40 Mn |
| Jun 30, 2022 | 77.27 Mn |
| Mar 31, 2022 | 69.82 Mn |
| Dec 31, 2021 | 60.20 Mn |
| Sep 30, 2021 | 35.27 Mn |